Dianthus Therapeutics, Inc.
DNTH
$85.74
-$0.41-0.48%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -72.40% | -91.05% | -88.32% | -102.46% | -100.61% |
| Total Depreciation and Amortization | -15.30% | 3.88% | -6.41% | 4.41% | 14.96% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 159.78% | 139.64% | 125.40% | 100.78% | 205.85% |
| Change in Net Operating Assets | 2,466.00% | 4,865.24% | 351.12% | 1,346.85% | -85.39% |
| Cash from Operations | -43.38% | -65.08% | -74.98% | -95.33% | -118.87% |
| Capital Expenditure | -105.15% | -102.86% | -26.19% | -1.61% | 24.22% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1.87% | 57.23% | 32.67% | -906.47% | -8,079.74% |
| Cash from Investing | -1.91% | 57.17% | 32.65% | -901.81% | -7,773.29% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2,441.27% | 3.77% | 36.63% | -82.33% | -82.55% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 23.90% | 97.52% | 99.12% | -100.00% | -101.85% |
| Cash from Financing | 2,587.02% | 9.59% | 49.19% | -88.35% | -89.20% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 293.30% | 125.81% | 118.02% | -209.84% | -204.22% |